955372-99-3

Upstream product

• 1450-14-2 1,1,1,2,2,2-hexamethyldisilane 
• 57946-56-2 2-fluoro-4-chloroaniline 
• 367-24-8 4-bromo-2-fluoroaniline 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 75-77-4 chloro-trimethyl-silane 
• 1009333-65-6 (3-fluoro-4-nitro-phenyl)-trimethylsilane 

Downstream Products

• 955373-00-9 4-chloro-N-[2-fluoro-4-(trimethylsilyl)phenyl]pyridin-3-amine 
• 1009333-67-8 ethyl 3-(4-trimethylsilyl-2-fluoro-phenylamino)-furo[3,2-c]pyridine-2-carboxylate 
• 1009333-98-5 ethyl 5-(2-fluoro-4-trimethylsilanyl-phenylamino)-furo[2,3-d]pyrimidine-6-carboxylate 
• 1009334-31-9 7-bromo-3-(2-fluoro-4-trimethylsilanylphenylamino)furo[3,2-c]pyridine-2-carboxylic acid ethyl ester 
• 1009334-44-4 3-(2-fluoro-4-trimethylsilanyl-phenylamino)-furo[3,2-c]pyridine-2,7-dicarboxylic acid 2-benzyl ester 7-ethyl ester 
• 1009334-48-8 2-dimethylcarbamoyl-3-(2-fluoro-4-trimethylsilanyl-phenylamino)-furo[3,2-c]pyridine-7-carboxylic acid ethyl ester 
• 1009334-60-4 7-fluoro-3-(2-fluoro-4-trimethylsilanyl-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ethyl ester 
• 1009334-74-0 4-chloro-3-(2-fluoro-4-trimethylsilanyl-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ethyl ester 
• 1168091-46-0 5-chloro-3-(2-fluoro-4-trimethylsilanyl-phenylamino)-pyrazine-2-carboxylic acid 
• 1168090-86-5 6-chloro-2-((2-fluoro-4-(trimethylsilyl)phenyl)amino)nicotinic acid 
• 1168091-26-6 6-chloro-5-fluoro-2-((2-fluoro-4-(trimethylsilyl)phenyl)amino)nicotinic acid 
• 1174552-29-4 2-[2-fluoro-4-(trimethylsilanyl)phenylamino]-5,5-dimethyl-7-oxo-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid ethyl ester 
• 1203662-57-0 4-(2-fluoro-4-trimethylsilanylphenylamino)-1-(toluene-4-sulfonyl)-1H-indazole-5-carboxylic acid methyl ester 
• 1203662-67-2 4-(2-fluoro-4-trimethylsilanylphenylamino)indazole-1,5-dicarboxylic acid di-tert-butyl ester 

Relevant academic research and scientific papers

CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula where R1, R2, R2a, R3, R3a, and X are as described herein.

TOPICAL FORMULATIONS

Provided herein are gelled topical formulations for the treatment of skin diseases comprising: a) a MEK inhibitor; b) one or more organic solvents in an amount of about 70% to about 99% by weight; and c) a gelling agent; wherein the one or more organic solvents are selected from the group consisting of C2-6 alcohol, a C2-6 alkylene glycol, a di-(C2-6 alkylene) glycol, a polyethylene glycol, C1-3 alkyl-(OCH2CH2)1-5-OH, DMSO, ethyl acetate, acetone, N-methyl pyrrolidone, benzyl alcohol, glycerin, and an oil; the gelling agent is hydroxypropyl cellulose having a molecular weight ranging from about 40,000 Dato about 2,500,000 Da; and wherein the gelled topical formulation has a viscosity of from 1 to 25,000 cps; and DMSO, when present, is combined with at least one other of said organic solvents such that DMSO is present in an amount of less than 50% by weight.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS

Provided herein are compounds and pharmaceutical compositions thereof for treating a birthmark in a subject in need thereof, wherein the compound is according to any one of formula (1), (II), (III), (IV), and (V). wherein X1, X2, X3, R1, R2, R2a, R13, R13a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS

Provided herein are compounds and pharmaceutical compositions thereof for treating a skin cancer in a subject in need thereof, wherein the compound is according to any one of formula (I), (II), (III), (IV), and (V): wherein X1, X2, X3, R1, R2, R2a, R13, Rl3a, R23, R23a, R23b, R33, R33a, R33b, R43, R43a, R51, R53, R53a, R53b, bond "a", and subscript n are described herein.

ISOINDOLONE DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE

The invention relates to isoindoloncs of formula, (I) with anti-cancer and/or anti- inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE

The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS

A series of 7-oxo-4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in m

AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE

The invention relates to azabenzofuranyl compounds of Formula (I) with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzofuranyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.